Ribonucleotide reductase (RRM1)
The enzyme that makes DNA building blocks from RNA building blocks. Gemcitabine's active form shuts it down and hydroxyurea quenches its catalytic radical, starving dividing cells of the nucleotides they need.
Overview
Ribonucleotide reductase converts ribonucleoside diphosphates into the deoxyribonucleotides used to make DNA, the rate-limiting step of DNA precursor supply. Gemcitabine diphosphate inhibits the RRM1 large subunit while gemcitabine triphosphate is built into DNA and stops chain extension, a self-potentiating combination that underlies its use in pancreatic, lung, bladder, ovarian and breast cancers. Hydroxyurea scavenges the tyrosyl radical of the small subunit and is used to control blood counts in myeloproliferative neoplasms and chronic myeloid leukaemia. High RRM1 expression is associated with gemcitabine resistance.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · The enzyme that makes DNA building blocks from RNA building blocks. Gemcitabine's active form shuts it down and hydroxyurea quenches its catalytic radical, starving dividing cells of the nucleotides they need.
- 1 · What it is
The enzyme that makes DNA building blocks from RNA building blocks. Gemcitabine's active form shuts it down and hydroxyurea quenches its catalytic radical, starving dividing cells of the nucleotides they need.
- 2 · What goes wrong in cancer
Large catalytic subunit of ribonucleotide reductase; target of gemcitabine diphosphate, with the small subunit RRM2 quenched by hydroxyurea.
- 3 · How drugs use it
No product in this corpus aims at Ribonucleotide reductase (RRM1) yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
External identifiers
Biology
Large catalytic subunit of ribonucleotide reductase; target of gemcitabine diphosphate, with the small subunit RRM2 quenched by hydroxyurea.
- Pancreatic, lung, bladder, ovarian and breast cancers treated with gemcitabine
- Myeloproliferative neoplasms treated with hydroxyurea
Latest papers
topQuery for this target: (TITLE:"Ribonucleotide reductase" OR ABSTRACT:"Ribonucleotide reductase" OR TITLE:"RRM1" OR ABSTRACT:"RRM1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Ribonucleotide reductase (RRM1), not a curated reading list.
Similar pages
not linked directly; found by shared links- CompanyMolecular Partners
Shares Bladder & urothelial cancer, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer.
- TreatmentABSK061
Shares Bladder & urothelial cancer, Non-small-cell lung cancer.
- CompanyProxygen
Shares Bladder & urothelial cancer, Non-small-cell lung cancer.
- CompanyNucleix
Shares Bladder & urothelial cancer, Non-small-cell lung cancer.
- TreatmentJK08
Shares Bladder & urothelial cancer, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer.
- TreatmentT3011
Shares Bladder & urothelial cancer, Non-small-cell lung cancer.
- IdeaSlow the tumour's mutation engine with APOBEC inhibitors during targeted therapy
Shares Bladder & urothelial cancer, Non-small-cell lung cancer.
- IdeaProtect hearing from cisplatin in adults as we now do in children
Shares Bladder & urothelial cancer, Non-small-cell lung cancer.